Hybridoma passage in vitro may result in reduced ability of antimannan antibody to protect against disseminated candidiasis

Infection and Immunity

Volumn 74, Issue 7, 2006, Pages 4310-4321

  Xin, Hong ^a   Cutler, Jim E ^a,b  

^a LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMANNAN ANTIBODY; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G3; IMMUNOGLOBULIN HEAVY CHAIN; IMMUNOGLOBULIN LIGHT CHAIN; IMMUNOGLOBULIN M; MANNAN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY B6.1; MONOCLONAL ANTIBODY C3.1; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIGEN BINDING; ARTICLE; CANDIDIASIS; COMPLEMENT ACTIVATION; COMPLEMENT FIXATION; CONTROLLED STUDY; GENETIC STABILITY; GLYCATION; HYBRIDOMA; IMMUNOGLOBULIN VARIABLE REGION; IN VITRO STUDY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; BASE SEQUENCE; BINDING SITES, ANTIBODY; CANDIDIASIS; CELL CULTURE TECHNIQUES; CELL LINE; HYBRIDOMAS; MANNANS; MICE; MOLECULAR SEQUENCE DATA;

EID: 33745608752     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/IAI.00234-06     Document Type: Article

References (52)

1. Anaissie, E., and G. P. Bodey. 1989. Nosocomial fungal infections. Old problems and new challenges. Infect. Dis. Clin. N. Am. 3:867-882.
2. Berenguer, J., M. Buck, F. Witebsky, F. Stock, P. A. Pizzo, and T. J. Walsh. 1993. Lysis-centrifugation blood cultures in the detection of tissue-proven invasive candidiasis. Diagn. Microbiol. Infect. Dis. 17:103-109.
3. Bodey, G. P. 1988. The emergence of fungi as major hospital pathogens. J. Hosp. Infect. 11:411-426.
4. Bromuro, C., A. Torosantucci, P. Chiani, S. Conti, L. Polonelli, and A. Cassone. 2002. Interplay between protective and inhibitory antibodies dictates the outcome of experimentally disseminated candidiasis in recipients of a Candida albicans vaccine. Infect. Immun. 70:5462-5470.
5. Carroll, W. L., E. Mendel, and S. Levy. 1988. Hybridoma fusion cell lines contain an aberrant kappa transcript. Mol. Immunol. 25:991-995.
6. Casadevall, A. 1995. Antibody immunity and invasive fungal infections. Infect. Immun. 63:4211-4218.
7. Casadevall, A., W. Cleare, M. Feldmesser, A. Glatman-Freedman, D. L. Goldman, T. R. Kozel, N. Lendvai, J. Mukherjee, L.-A. Pirofski, J. Rivera, A. L. Rosas, M. D. Scharff, P. Valadon, K. Westin, and Z. Zhong. 1998. Characterization of a murine monoclonal antibody to Cryptococcus neoformans polysaccharide that is a candidate for human therapeutic studies. Antimicrob. Agents Chemother. 42:1437-1446.
8. Casadevall, A., E. Dadachova, and L.-A. Pirofski. 2004. Passive antibody therapy for infectious diseases. Nature Rev. 2:695-703.
9. Casadevall, A., and L.-A. Pirofski. 2004. New concepts in antibody-mediated immunity. Infect. Immun. 72:6191-6196.
10. Clackson, T., H. R. Hoogenboom, A. D. Griffiths, and G. Winter. 1991. Making antibody fragments using phage display libraries. Nature 352:624-628.
11. Cutler, J. E. 2005. Defining criteria for anti-mannan antibodies to protect against candidiasis. Curr. Mol. Med. 5:383-392.
12. de Mattes Grosso, D., S. R. de Almeida, M. Mariano, and J. D. Lopes. 2003. Characterization of gp70 and anti-gp70 monoclonal antibodies in Paracoccidioides brasiliensis pathogenesis. Infect. Immun. 71:6534-6542.
13. Feinstein, A., N. Richardson, and M. J. Taussig. 1986. Immunoglobulin flexibility in complement activation. Immunol. Today 7:169-174.
14. Fidel, P. L., M. E. Lynch, and J. D. Sobel. 1993. Candida-specific cell-mediated immunity is demonstrable in mice with experimental vaginal candidiasis. Infect. Immun. 61:1990-1995.
15. Fisher-Hoch, S. P., and L. Hutwagner. 1995. Opportunistic candidiasis: an epidemic of the 1980s. Clin. Infect. Dis. 21:897-904.
16. Han, Y., and J. E. Cutler. 1995. Antibody response that protects against disseminated candidiasis. Infect. Immun. 63:2714-2719.
17. Han, Y., and J. E. Cutler. 1997. Assessment of a mouse model of neutropenia and the effect of an anti-candidiasis monoclonal antibody in these animals. J. Infect. Dis. 175:1169-1175.
18. Han, Y., T. Kanbe, R. Cherniak, and J. E. Cutler. 1997. Biochemical characterization of Candida albicans epitopes that can elicit protective and nonprotective antibodies. Infect. Immun. 65:4100-4107.
19. Han, Y., T. R. Kozel, M. X. Zhang, R. S. MacGill, M. C. Carroll, and J. E. Cutler. 2001. Complement is essential for protection by an IgM and an IgG3 monoclonal antibody against experimental hematogenously disseminated candidiasis. J. Immunol. 167:1550-1557.
20. Han, Y., R. P. Morrison, and J. E. Cutler. 1998. A vaccine and monoclonal antibodies that enhance mouse resistance to Candida albicans vaginal infection. Infect. Immun. 66:5771-5776.
21. Han, Y., M. H. Riesselman, and J. E. Cutler. 2000. Protection against candidiasis by an immunoglobulin G3 (IgG3) monoclonal antibody specific for the same mannotriose as an IgM protective antibody. Infect. Immun. 68:1649-1654.
22. Han, Y., M. A. Ulrich, and J. E. Cutler. 1999. Candida albicans mannan extract-protein conjugates induce a protective immune response against experimental candidiasis. J. Infect. Dis. 179:1477-1484.
23. Hartman, A. B., and S. Rudikoff. 1984. VH genes encoding the immune response to beta-(1,6)-galactan: somatic mutation in IgM molecules. EMBO J. 3:3023-3030.
24. Horgan, C., K. Brown, and S. H. Pincus. 1990. Alteration in H chain V region affects complement activation by chimeric antibodies. J. Immunol. 145:2527-2532.
25. Horgan, C., K. Brown, and S. H. Pincus. 1992. Effect of H chain V region on complement activation by immobilized immune complexes. J. Immunol. 149:127-135.
26. Hostetter, M. K. 1996. New insights into candidal infections. Adv. Pediatr. 43:209-230.
27. Idusogie, E. E., P. Y. Wong, L. G. Presta, H. Gazzano-Santoro, K. Totpal, M. Ultsch, and M. G. Mulkerrin. 2001. Engineered antibodies with increased activity to recruit complement. J. Immunol. 166:2571-2575.
28. Klaus, G. G. B., M. B. Pepys, K. Kitajima, and B. A. Askonas. 1979. Activation of mouse complement by different classes of mouse antibody. Immunology 38:687-695.
29. Li, R.-K., and J. E. Cutler. 1991. A cell surface/plasma membrane antigen of Candida albicans. J. Gen. Microbiol. 137:455-464.
30. Matthews, R. C., G. Rigg, S. Hodgetts, T. Carter, C. Chapman, C. Gregory, C. Illidge, and J. Burnie. 2003. Preclinical assessment of the efficacy of mycograb, a human recombinant antibody against fungal HSP90. Antimicrob. Agents Chemother. 47:2208-2216.
31. Miletic, V. D., and M. M. Frank. 1995. Complement-immunoglobulin interactions. Curr. Biol. 7:41-47.
32. Mukherjee, J., G. Nussbaum, M. D. Scharff, and A. Casadevall. 1995. Protective and nonprotective monoclonal antibodies to Cryptococcus neoformans originating from one B cell. J. Exp. Med. 181:405-409.
33. Nitz, M., C.-C. Ling, A. Otter, J. E. Cutler, and D. R. Bundle. 2002. The unique solution structure and immunochemistry of the Candida albicans β-1,2-mannopyranan cell wall antigens. J. Biol. Chem. 277:3440-3446.
34. Orlandi, R., D. H. Gussow, P. T. Jones, and G. Winter. 1989. Cloning immunoglobulin variable domains for expression by the polymerase chain reaction. Proc. Natl. Acad. Sci. USA 86:3833-3837.
35. Polonelli, L., W. Magliani, S. Conti, L. Bracci, L. Lozzi, P. Neri, D. Adriani, F. De Bernardis, and A. Cassone. 2003. Therapeutic activity of an engineered synthetic killer antiidiotypic antibody fragment against experimental mucosal and systemic candidiasis. Infect. Immun. 71:6205-6212.
36. Rogozin, I. B., and M. Diaz. 2004. Cutting edge: DGYW/WRCH is a better predictor of mutability at G:C bases in Ig hypermutation than the widely accepted RGYW/WRCY motif and probably reflects a two-step activation-induced cytidine deaminase-triggered process. J. Immunol. 172:3382-3384.
37. Rogozin, I. B., and N. A. Kolchanov. 1992. Somatic hypermutagenesis in immunoglobulin genes. II. Influence of neighbouring base sequences on mutagenesis. Biochim. Biophys. Acta 1171:11-18.
38. Schaberg, D. R., D. H. Culver, and R. P. Gayner. 1991. Major trends in the microbial etiology of nosocomial infection. Am. J. Med. 16:72S-75S.
39. Schäble, K. F., R. Thiebe, A. Bensch, J. Brensing-Küppers, V. Helm, T. Kirschbaum, R. Lamn, M. Ohnrich, S. Pourrajabi, F. Röschenthaler, J. Schwendinger, D. Wichelhaus, I. Zocher, and H. G. Zachau. 1999. Characteristics of the immunoglobulin VK genes, pseudogenes, relics and orphons in the mouse genome. Eur. J. Immunol. 29:2082-2086.
40. Shibata, N., M. Arai, E. Haga, T. Kikuchi, M. Najima, T. Satoh, H. Kobayashi, and S. Suzuki. 1992. Structural identification of an epitope of antigenic factor 5 in mannans of Candida albicans NIH B-792 (serotype B) and J-1012 (serotype A) as beta-1,2-linked oligomannosyl residues. Infect. Immun. 60:4100-4110.
41. Shibata, N., K. Hisamichi, T. Kikuchi, H. Kobayashi, Y. Okawa, and S. Suzuki. 1992. Sequential nuclear magnetic resonance assignment of β-1,2-linked mannooligosaccharides isolated from the phosophomannan of the pathogenic yeast Candida albicans NIH B-792 strain. Biochemistry 31:5680-5686.
42. Spira, G., A. Bargellesi, J.-L. Teillaud, and M. D. Scharff. 1984. The identification of monoclonal class switch variants by sib selection and an ELISA assay. J. Immunol. Methods 74:307-315.
43. Tachibana, H., N. Matsumoto, X.-J. Cheng, H. Tsukamoto, and E. Yoshihara. 2004. Improved affinity of a human anti-Entamoeba histolytica Gal/Ga1NAc lectin Fab fragment by a single amino acid modification of the light chain. Clin. Diagn. Lab. Immunol. 11:1085-1088.
44. Taylor, B., J. J. Wright, S. Arya, D. E. Isenman, M. J. Shulman, and R. H. Painter. 1994. C1q binding properties of monomer and polymer forms of mouse IgM μ-chain variants. J. Immunol. 153:5303-5313.
45. Tollemar, J., N. Gross, N. Dolgiras, C. Jarstrand, O. Ringden, and L. Hammarstrom. 1999. Fungal prophylaxis by reduction of fungal colonization by oral administration of bovine anti-Candida antibodies in bone marrow transplant recipients. Bone Marrow Transplant. 23:283-290.
46. Torosantucci, A., C. Bromuro, P. Chiani, F. DeBernardis, F. Berti, C. Galli, F. Norelli, C. Bellucci, L. Polonelli, P. Costantino, R. Rappuoli, and A. Cassone. 2005. A novel glyco-conjugate vaccine against fungal pathogens. J. Exp. Med. 202:597-606.
47. Voss, A., J. L. M. L. le Noble, F. M. Verduyn Lunel, N. A. Foudraine, and J. F. G. M. Meis. 1997. Candidemia in intensive care unit patients: risk factors for mortality. Infection 25:8-10.
48. Wagner, S. D., C. Milstein, and M. S. Neuberger. 1995. Codon bias targets mutation. Nature 376:732.
49. Wenzel, R. P. 1995. Nosocomial candidemia: risk factors and attributable mortality. Clin. Infect. Dis. 20:1531-1534.
50. Wright, J. F., M. J. Shulman, D. E. Isenman, and R. H. Painter. 1988. C1 binding by murine IgM. J. Biol. Chem. 263:11221-11226.
51. Zhang, M. X., M. C. Bohlman, C. Itatani, D. R. Burton, P. W. H. I. Parren, S. C. St. Jeor, and T. R. Kozel. 2006. Human recombinant antimannan immunoglobulin G1 antibody confers resistance to hematogenously disseminated candidiasis in mice. Infect. Immun. 74:362-369.
52. Zhang, M. X., and T. R. Kozel. 1998. Mannan-specific immunoglobulin G antibodies in normal human serum accelerate binding of C3 to Candida albicans via the alternative complement pathway. Infect. Immun. 66:4845-4850.